Medical Discoveries | Pharma Voice | Experimental | Safety Innovations | Certifications & Approvals | Laboratories
Sandoz’s Enbrel biosim case turned away at SCOTUS, giving Amgen’s blockbuster 8 more years of free rein
Charles River lays out $293M to snap up viral vector specialist Vigene, its 2nd M&A deal this year
ACC 2021: Regeneron’s Evkeeza aces triglyceride control, but only in certain patients
ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients
ACC 2021: AstraZeneca’s Farxiga failed to help COVID-19 patients, but it’s safe for them to use
Moderna, Pfizer join the popular crowd, catapulting into the top 10 of America’s favorite companies
Apellis’ Soliris rival Empaveli snags FDA approval in PNH
Can a small biotech challenge Alexion’s Soliris? With Empaveli’s FDA nod, Apellis can give it a try
ACC 2021: Novartis looks for silver linings in Entresto’s narrow loss to an ACE inhibitor in heart attack patients
ACC 2021: Novartis looks for silver linings in Entrestro’s narrow loss to an ACE inhibitor in heart attack patients
After back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up its long shot biosimilars case against Enbrel maker Amgen.
The author of this article is Amit Pathak, NLP Trainer and Mental Wellness Coach For people above 40, or even less, Hypertension is a dangerous,
The author of this article is Mr. Indroneil Mukerjee, Bach flower Therapist. A couple of years ago, Manisha came to me for Bach Flower therapy, having
A few short months after Charles River Laboratories acquired Cognate BioServices, the company is folding yet another CDMO into its cell and gene network, signing more than
Last Friday, the Irish health service was hit with a ‘significant’ ransomware attack resulting in its IT systems being temporarily shut down to ‘assess [the]
A gene therapy developed by Biogen for the rare inherited eye disease X-linked retinitis pigmentosa (XLRP) has failed to meet the primary endpoint in a
MSD’s immunotherapy Keytruda has gained UK National Institute for Health and Care Excellence (NICE) backing as a first-line treatment for certain colorectal cancer patients. The
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups. In February, the companies announced that
Regeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of cholesterol. But thanks
With an approval filing already on the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients
